XML 27 R13.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Inventory | 12 Months Ended
--- | ---
Dec. 31, 2023
Inventory Disclosure [Abstract] |
Inventory | Inventory At December 31, 2023 and 2022, the Company’s inventory primarily related to ORLADEYO. Additionally, inventory included RAPIVAB and peramivir, which is manufactured for the Company’s partners. The Company’s inventories consisted of the following (in thousands):
| December 31,
| 2023 |  | 2022
Raw materials | $ | 6,449 |  |  | $ | 8,906 |
Work-in-process | 17,591 |  |  | 14,990 |
Finished goods | 6,242 |  |  | 4,814 |
Total inventory | $ | 30,282 |  |  | $ | 28,710 |
Reserves | (1,599) |  |  | (1,177) |
Total inventory, net | $ | 28,683 |  |  | $ | 27,533 |
During the years ended December 31, 2023 and 2022, the Company evaluated its inventory levels and associated expiration dating relative to the latest sales forecasts for ORLADEYO, RAPIVAB and peramivir and recorded estimated inventory valuation reserves for those inventories at risk of obsolescence.

X
- References No definition available. + Details
Name: | us-gaap_InventoryDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//330/tableOfContent + Details
Name: | us-gaap_InventoryDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration